Clinical Trial

Probiotics for Constipation Relief in Adults

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the efficacy and safety of Bifidobacterium animalis subsp. lactis BLa36 in adults with functional constipation. In this randomized, double-blind, placebo-controlled trial, participants will receive BLa36 supplementation or placebo for 8 weeks. Clinical outcomes will be assessed using validated gastrointestinal symptom scales, stool characteristics, and quality-of-life measures. In addition, changes in inflammatory and immune markers, gut microbiota composition, metabolic indicators, and gut-brain axis-related parameters will be evaluated to comprehensively determine the effects of BLa36 on intestinal function and overall health.
Protocol Amendment History 2 changes
notable Enrollment increased: 70 -> 105 participants 2026-06-10
minor Trial arms changed: 2 -> 3 2026-06-10
Trial Details
NCT Number NCT07507955
Lead Sponsor Wecare Probiotics Co., Ltd.
Conditions Functional Constipation
Enrollment 105 participants
Start Date 2026-06-10
Primary Completion 2026-11-30 (estimated)
Study Completion 2027-01-20 (estimated)
Updated on ClinicalTrials.gov 2026-06-09